On this page
How do you prepare the drug substance control package in CTD 3.2.S.4?
Connect every proposed specification criterion to the procedure measuring it, evidence that the procedure is suitable, relevant batch results and the scientific justification. Keep material scope, units, method versions and result qualifiers consistent. A specification table alone does not explain why its tests and limits are appropriate.
Before you begin
M4Q(R1) S.4 content organization; analytical validation should use the applicable current guidance rather than historical Q2A/Q2B references.
What you will prepare: A reconciled control package whose limits, methods, data and rationale describe the same substance and process.
S.4.1–S.4.3: connect each criterion to a working measurement
In S.4.1, present the proposed specification with test, method identifier and acceptance criterion for the actual substance instance. Confirm units, reporting basis and any distinct specification scopes. Take values from the controlled scientific proposal, never from a generic template.
In S.4.2, give the analytical procedures needed to understand the testing: sample preparation, relevant standards, equipment/conditions, calculations and interpretation as applicable. In S.4.3, provide the validation information and experimental evidence supporting those procedures for their intended uses. Match the method version used in validation to the proposed procedure; explain changes and their assessment. FDA's Q2(R2) is final March 2024, so the Q2A/Q2B references printed in M4Q are not the current revision entrypoint.
S.4.4–S.4.5: show evidence and explain the proposal
For S.4.4, identify each batch, site, scale, process version, date/use and analytical results as relevant. Preserve actual reported results and qualifiers; a column containing only “passes” cannot replace quantitative information when that is needed to assess the proposal. Explain which batches support nonclinical, clinical, stability and commercial-process conclusions.
For S.4.5, justify the selection of tests and criteria using characterization, impurity assessment, manufacturing capability, stability and applicable scientific guidance. Distinguish the observed range from the proposed limit and explain the connection. If a limit relies on a safety qualification, locate that evidence and confirm the same impurity/material context. Wider limits are not justified merely because they are convenient for manufacturing.
Worked review: method sensitivity does not support the proposed limit
Fictional exercise: a proposed impurity criterion is below the demonstrated quantitation range of the method used for supporting batch results. The table still reports every batch as acceptable.
Ask the analytical owner to assess fitness for purpose and the interpretation of the results. Obtain appropriately supported measurement capability or revise the scientifically justified control proposal through the responsible process. Reconcile the method, validation, batch presentation and specification together. Do not convert a less-than result into zero, and do not claim the criterion has been demonstrated while its analytical basis remains unresolved.
Review each specification row through five linked records
Use this editorial trace for each consequential quality attribute. It follows the S.4 task without prescribing the tests or criteria for an unknown substance.
| Record | Exact question to answer |
|---|---|
| S.4.1 specification | What material, test, reporting basis and criterion are proposed? |
| S.4.2 procedure | What method version produces the result and how is it calculated? |
| S.4.3 validation | What evidence supports that method for this purpose and range? |
| S.4.4 batch analysis | Which batches were tested, using which procedure and result convention? |
| S.4.5 justification | Why do the selected tests and criteria address this substance's quality? |
Trace in both directions. Starting from the specification reveals missing methods or rationale. Starting from batch data can reveal a procedure or material version that the proposal no longer covers. A result with a less-than qualifier should retain that meaning throughout the trace.
Decision example: the method changed after the batches in the supporting table were tested. Identify the change and obtain its analytical assessment. The options are not simply to relabel the old results or discard them; the technical owner must establish what comparison and conclusion are supported.
Ask the analytical reviewer to assess suitability against the current Q2(R2) source for the intended use. Reconcile impurity criteria with characterization and trends with stability. The writer's deliverable is a consistent evidence chain, not a newly invented limit.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a batch certificate justify a specification limit?
A certificate supplies results for identified material under specified tests; it is not by itself the scientific rationale for a proposed limit. The justification should connect relevant characterization, manufacturing, stability and other applicable evidence to the criterion being proposed.
Can a result below quantitation be entered as zero?
No. Preserve the reported qualifier and the method limitation. A value below a quantitation boundary is not proof that the substance is absent. Ask the analytical owner how the result should be interpreted for the proposed criterion and comparison.
Should a new method version simply replace the old identifier in batch tables?
No. Identify which version generated each result and obtain an assessment of the change and data comparability. Updating a method name cannot change how historical measurements were made. Reconcile procedures, validation and result interpretation before finalizing the control package.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.2.S.4.1–3.2.S.4.5, printed page 10.
Guidance
FDA Q2(R2): Validation of Analytical Procedures ↗Final, March 2024; sections II.A–D (validation study, lifecycle, reportable range, stability indication). PDF and current FDA status page checked; the older Q2A/Q2B citations in M4Q are historical. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.2.S.4. A heading identifies placement, not mandatory applicability.